Failure to Continue Lipid-Lowering Drug Use Following the Withdrawal of Cerivastatin

Drug Safety

Volumn 27, Issue 1, 2004, Pages 63-70

  Mantel Teeuwisse, Aukje K ^a   Klungel, Olaf H ^a   Egberts, Toine C G ^a,b   Verschuren, W M Monique ^c   Porsius, Arijan J ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b GGZ Midden Brabant   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PHARMACY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SEX RATIO; SIDE EFFECT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; COMMUNITY PHARMACY SERVICES; DATA INTERPRETATION, STATISTICAL; DATABASE MANAGEMENT SYSTEMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NETHERLANDS; PATIENT COMPLIANCE; PATIENT DROPOUTS; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIDINES;

EID: 0442307498     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427010-00004     Document Type: Article

References (26)

1. Weber W. Drug firm withdraws statin from market. Lancet 2001; 358: 568
2. West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997; 18: 1718-24
3. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52
4. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins in patients with acute coronary syndromes [erratum]. Circulation 2003: 107: e27
5. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998; 352: 1830-1
6. Bouvy ML. Egberts TC. Consequences of a change in reimbursement status on prescription patterns. Eur J Clin Pharmacol 2000; 56: 511-2
7. Hope S. Third generation oral contraceptives: 12% of women stopped taking their pill immediately they heart CSM's warning [letter]. BMJ 1996; 312: 576
8. Farmer RD, Williams TJ, Simpson EL, et al. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database. BMJ 2000; 321: 477-9
9. Mullins ME. Horowitz BZ, Linden DH, et al. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998; 280: 157-8
10. Herings RM, Bakker A, Stricker BH, et al. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-40
11. Dutch Medicines Evaluation Board. Dear doctor letter [online]. Available from URL: http://www.cbg-meb.nl/nl/docs/nieuws/ pb-lipobay.pdf [Accessed 2003 Dec 1]
12. Dutch Medicines Evaluation Board. Dear doctor letter. Press release by Bayer Pharmaceuticals [online]. Available from URL: http://www.cbg-meb.nl/nl/ docs/nieuws/dd-lipobay-2. pdf [Accessed 2003 Dec 1]
13. World Health Organization. Guidelines for ATC Classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology-Nordic Council on Medicines, 2001
14. Lau HS, de Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment [letter]. J Clin Epidemiol 1997; 50: 619-25
15. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31
16. Simons LA, Simons J, McManus P, et al. Discontinuation rates for use of statins are high. BMJ 2000; 321: 1084
17. Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002; 53: 375-8
18. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458-62
19. Abookire SA, Karson AS, Fiskio J, et al. Use and monitoring of 'statin' lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 53-8
20. Jukema JW, Simoons ML. Treatment and prevention of coronary heart disease by lowering serum cholesterol levels; from the pioneer work of C.D. de Langen to the third 'Dutch Consensus on Cholesterol'. Acta Cardiol 1999; 54: 163-8
21. Second Joint Task Force of European and other Societies. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-503
22. Weaver JS, Doering PL. Cerivastatin and the dissemination of adverse event information. Ann Pharmacother 2002; 36: 1099-103
23. Varma S, McElnay JC, Hughes CM, et al. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacotherapy 1999; 19: 860-9
24. Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health Syst Pharm 1999; 56: 1339-42
25. Kaplan RC, Psaty BM, Kriesel D, et al. Replacing short-acting nifedipine with alternative medications at a large health maintenance organization. Am J Hypertens 1998; 11: 471-7
26. Schiff GD. Keehr LM. Sai TT, et al. High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic. Pharmacoepidemiol Drug Saf 2002; 11: 643-5